Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda is committed to discovering and delivering life-transforming treatments, guided by its commitment to patients, its people, and the planet. The company focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). Takeda also makes targeted R&D investments in Plasma-Derived Therapies and Vaccines. Takeda aims to bring Better Health and a Brighter Future to people worldwide by translating science into highly innovative medicines.
Serves as the global corporate headquarters, overseeing worldwide operations, strategic planning, research and development direction, and corporate governance for the entire Takeda group.
The Takeda Global Headquarters building, completed in 2018, is a state-of-the-art, sustainable facility designed to promote collaboration and innovation. It features open-plan workspaces, advanced communication technologies, and employee wellness amenities.
Takeda's Tokyo HQ fosters a work culture rooted in 'Takeda-ism' (Integrity, Fairness, Honesty, Perseverance) and patient-centricity. It promotes collaboration, innovation, and continuous learning, supported by modern facilities designed for employee well-being and flexible work styles. There's a strong emphasis on diversity, equity, and inclusion.
The Tokyo Global Headquarters is a symbol of Takeda's long heritage in Japan and its position as a leading global biopharmaceutical company. It serves as the nerve center for strategic decision-making, R&D oversight, and global business operations, connecting its worldwide network.
Takeda operates in approximately 80 countries and regions worldwide, with a significant presence in Japan, the United States, Europe, Latin America, Africa, the Middle East, and Asia. Its global functions include extensive research and development facilities, a network of manufacturing plants, comprehensive commercial operations (sales, marketing, and distribution), and various corporate support services, all dedicated to addressing unmet medical needs globally.
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku
Tokyo
Tokyo
Japan
Address: 95 Hayden Avenue, Lexington, MA 02421, USA
Manages and executes Takeda's strategy within the U.S. pharmaceutical market, focusing on delivering innovative medicines to American patients, engaging with healthcare providers and institutions, and navigating the U.S. regulatory and reimbursement landscape.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Takeda' leadership includes:
Takeda has been backed by several prominent investors over the years, including:
Takeda has actively shaped its leadership over the past 12 months (approx. May 2023 - May 2024), notably appointing new executives to spearhead its data & technology, corporate affairs, and human resources functions. These strategic hires underscore the company's focus on digital transformation, stakeholder engagement, and talent development to drive future growth. No major C-suite departures were prominently announced during this period.
Discover the tools Takeda uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Takeda Pharmaceutical primarily uses the 'firstname.lastname@takeda.com' email format for its employees. Variations might exist but this is the most common one.
firstname.lastname@takeda.com
Format
jane.doe@takeda.com
Example
85%
Success rate
takeda.com • May 9, 2024
Takeda announced its financial results for the full fiscal year 2023, highlighting resilience despite loss of exclusivity impacts. The company reported strong core revenue growth and outlined expectations for a return to overall growth in fiscal year 2024, driven by its Growth and Launch Products....more
takeda.com • April 26, 2024
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for Fruzaqla (fruquintinib) for adult patients with previously treated metastatic colorectal cancer (mCRC)....more
takeda.com • February 29, 2024
Takeda announced that the Phase 3 ADMIRE-CD II study evaluating Alofisel (darvadstrocel) for the treatment of complex Crohn's perianal fistulas (CPF) did not meet its primary endpoint of combined remission at 24 weeks. The safety profile was consistent with previous studies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Takeda, are just a search away.